| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.65, 0.99] | | < 1 | | 0% | 1 study (1/-) | 98.0 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 0.75 [0.61, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 1.49 [1.01, 2.21] | | > 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (grade 3-4) | 1.12 [0.73, 1.73] | | < 1 | | 0% | 1 study (1/-) | 30.2 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.27 [0.56, 2.87] | | < 1 | | 0% | 1 study (1/-) | 28.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.64 [1.38, 5.07] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 2.05 [0.69, 6.09] | | < 1 | | 0% | 1 study (1/-) | 9.9 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.12 [0.76, 1.65] | | < 1 | | 0% | 1 study (1/-) | 27.9 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.00 [0.32, 3.15] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 4.03 [0.18, 89.81] | | < 1 | | 0% | 1 study (1/-) | 19.3 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.50 [0.02, 14.95] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.08 [0.63, 1.86] | | < 1 | | 0% | 1 study (1/-) | 39.1 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.49 [0.12, 2.00] | | < 1 | | 0% | 1 study (1/-) | 83.8 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.50 [0.04, 5.53] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.25 [0.01, 5.54] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.12 [0.01, 2.34] | | < 1 | | 0% | 1 study (1/-) | 91.6 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.68 [0.40, 7.12] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 4.05 [0.45, 36.57] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 6.07 [0.30, 121.85] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.27 [0.69, 2.33] | | < 1 | | 0% | 1 study (1/-) | 22.1 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.00 [0.14, 7.16] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 1.04 [0.71, 1.51] | | < 1 | | 0% | 1 study (1/-) | 42.4 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 6.07 [0.30, 121.85] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 8.13 [0.43, 154.66] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.18 [0.67, 2.09] | | < 1 | | 0% | 1 study (1/-) | 28.1 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.66 [0.11, 4.01] | | < 1 | | 0% | 1 study (1/-) | 67.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 0.50 [0.02, 14.95] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.03 [0.62, 1.73] | | < 1 | | 0% | 1 study (1/-) | 44.8 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.72 [0.28, 1.82] | | < 1 | | 0% | 1 study (1/-) | 75.8 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.50 [0.04, 5.53] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.50 [0.04, 5.53] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.25 [0.03, 2.22] | | < 1 | | 0% | 1 study (1/-) | 89.2 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.00 [0.32, 3.15] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.75 [0.17, 3.37] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.51 [0.42, 5.44] | | < 1 | | 0% | 1 study (1/-) | 26.3 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.50 [0.02, 14.95] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 1.27 [0.69, 2.33] | | < 1 | | 0% | 1 study (1/-) | 22.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.66 [0.11, 4.01] | | < 1 | | 0% | 1 study (1/-) | 67.2 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 1.12 [0.77, 1.63] | | < 1 | | 0% | 1 study (1/-) | 28.3 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 1.54 [0.67, 3.50] | | < 1 | | 0% | 1 study (1/-) | 15.3 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.00 [0.06, 16.09] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 6.07 [0.30, 121.85] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.28 [0.73, 2.25] | | < 1 | | 0% | 1 study (1/-) | 19.6 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.50 [0.09, 2.73] | | < 1 | | 0% | 1 study (1/-) | 78.9 % | NA | not evaluable | | non important | - |
